Ekuiti Nasional Berhad announced that it invested in Ain Medicare Sdn Bhd a home-grown manufacturer of sterile parenteral pharmaceutical products. The investment, made via Ekuinas’ RM1 billion Tranche IV fund, will see investment arm acquire a strategic minority shareholding in the Company.
Aliff Omar Mohamad Omar, Chief Executive Officer of Ekuinas, said, “Recognising healthcare as a priority industry for Ekuinas, the pharmaceuticals subsector plays a key role in higher-value industrial growth and national resilience. Ain Medicare has established itself as a homegrown leader in sterile parenteral products, with a proven 30-year track record, diversified customer base and strong R&D pipeline.”
Founded in 1993 and headquartered in Kota Bharu, Kelantan, Ain Medicare has built a niche focus on sterile parenteral pharmaceutical products. Its diverse portfolio addresses a wide spectrum of common therapeutic needs, from intravenous solutions and small volume injectables to irrigation solutions and haemodialysis concentrates, which are essential for hospitalised and dialysis patients as well as other critical care needs. The Company’s existing customer base includes the Government of Malaysia, private healthcare providers and international markets. Ain Medicare currently operates 7 manufacturing facilities located in Kota Bharu and Kulim.
